Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00057720
Status:
COMPLETED
Last Update Posted:
2011-07-25
First Post:
2003-04-07
Brief Title:
TLK286 Telcyta vs DoxilCaelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
Sponsor:
Telik
Organization:
Telik
Study Overview
Official Title:
Phase 3 Randomized Study of TLK286 Telcyta Versus DoxilCaelyx or Hycamtin as Third-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer ASSIST-1 Assessment of Survival In Solid Tumors-1
Status:
COMPLETED
Status Verified Date:
2006-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with DoxilCaelyx or Hycamtin in the intent-to-treat ITT populations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None